齐拉西酮治疗精神分裂症临床对照研究

Clinical comparative study of ziprasidone in the treatment of schizophrenia.

目的比较齐拉西酮和利培酮治疗精神分裂症的疗效和安全性,以及对认知功能的影响。方法将52例精神分裂症患者,随机分为齐拉西酮组(26例)和利培酮组(26例),疗程6周。采用阳性和阴性症状量表(PANSS)、韦氏记忆量表修订版(WMS-RC)和副反应量表(TESS)进行评定。结果治疗6周后,齐拉西酮组显效率为61.5%、总有效率为84.6%;利培酮组分别为65.4%和80.8%,两组疗效差异无显著性。两组治疗后WMS-RC的短时记忆、瞬时记忆和记忆商数均明显高于治疗前,两组间比较差异均无显著性。两组不良反应的发生率无明显差异,且程度均较轻。结论齐拉西酮与利培酮治疗精神分裂症患者疗效相当,依从性好,能明显改善患者的认知功能。

Objective To compare the clinical efficacy,safety and the effect on cognitive function of ziprasidone and risperidone in the treatment of schizophrenia. Methods Fifty-two patients with schizophrenia were randomly assigned to two groups, study groups treated with ziprasidone（n=26） and control group with risperidone （n=26）for 6 weeks. The Positive and Negative Symptoms Scale（PANSS）, Wechsler Memory SCale（WMS-RC）and Treatment Emergent Symptoms scale （TESS） were used to evaluate the effects and side effects before and after the treatment. Results After 6 weeks treatment,the marked improvement rate was 61.5% and effective rate was 84.6% in ziprasidone group while 65. 4% and 80. 8% in risperidone group, and there were no significant differences between two groups. The short-term memory,immediate memory and memory quotient of WMS-RC increased significantly after treatment in both groups and no difference in WMS-RC was found between them. The incidence of adverse effects in two groups had no significant difference and the side effects of both groups were less. Conclusion Ziprasidone is as effective as risperidone for the treatment of schizophrenia and has good compliane. It can improve the cognitive function in schizophrenic patients.